Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17871293 | 0.81 | ADAMTS5 (0.56) | ADAMTS4ADAMTS5ADAM17MMP2 | |
| SCHEMBL23901406 | 0.77 | ADAMTS4 (0.35) | ADAMTS4ADAMTS5 | |
| SCHEMBL23745399 | 0.74 | ADAMTS5 (0.43) | ADAMTS4ADAMTS5ADAM17MMP2 | |
| SCHEMBL22062950 | 0.73 | ADAMTS5 (0.67) | ADAMTS4ADAMTS5ADAM17MMP2 | |
| SCHEMBL21473423 | 0.73 | SMN1; SMN2 (0.48) | ADAMTS4ADAMTS5ADAM17MMP2 | |
| SCHEMBL24182506 | 0.71 | ADAMTS7 (0.51) | ADAMTS4ADAMTS5MMP2 | |
| SCHEMBL23366977 | 0.71 | ADAMTS7 (0.51) | ADAMTS4ADAMTS5MMP2 | |
| SCHEMBL23354017 | 0.71 | ADAMTS7 (0.61) | ADAMTS4ADAMTS5MMP2 | |
| SCHEMBL23354182 | 0.71 | ADAMTS7 (0.61) | ADAMTS4ADAMTS5MMP2 | |
| SCHEMBL20708582 | 0.71 | ADAMTS5 (0.42) | ADAMTS4ADAMTS5ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | ADAMTS4 4/4885ADAMTS5 2/4885ADAM17 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.